Prion protein with Y145STOP mutation induces mitochondria-mediated apoptosis and PrP-containing deposits in vitro

Naomi S Hachiya1, Kota Watanabe, Makiko Y Kawabata

  • 1Department of Cortical Function Disorders, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8502, Japan.

Insights

A Gerstmann-Straussler-Scheinker disease mutation (Y145STOP) causes a truncated prion protein (PrP) to localize to mitochondria. This aberrant mitochondrial localization triggers cell death, offering insights into neurotoxicity.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Prion Diseases

Background:

  • Gerstmann-Straussler-Scheinker disease (GSS) is a rare, inherited prion disease.
  • The Y145STOP mutation is a pathogenic truncation linked to GSS.
  • Understanding the molecular mechanisms of GSS neurotoxicity is crucial.

Purpose of the Study:

  • To investigate the cellular effects of the pathogenic Y145STOP mutation in GSS.
  • To determine the subcellular localization and impact of truncated prion protein (PrP) constructs.
  • To elucidate the molecular basis of neurotoxicity associated with the Y145STOP mutation.

Main Methods:

  • Utilized GFP-PrP constructs for real-time imaging in living cells (N2a and HpL3-4 cell lines).
  • Confirmed aberrant mitochondrial localization using Western blot analysis.
  • Assessed mitochondrial function (membrane potential, cytochrome c release) and DNA fragmentation.
  • Employed immunoelectron microscopy to visualize PrP deposits in mitochondria.

Main Results:

  • GFP-PrP(1-144) exhibited aberrant mitochondrial localization, unlike full-length GFP-PrP.
  • This truncated PrP induced mitochondrial dysfunction, cytochrome c release, and DNA fragmentation.
  • Electron-dense deposits, co-localizing with mitochondrial markers, were observed within mitochondria.

Conclusions:

  • The Y145STOP mutation leads to a truncated PrP fragment that mislocalizes to mitochondria.
  • Aberrant mitochondrial localization of truncated PrP triggers apoptotic pathways and neurotoxicity.
  • These findings provide insights into the pathogenesis of GSS and potential therapeutic targets.

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Mitochondrial Precursor Proteins01:39

Mitochondrial Precursor Proteins

Mitochondrial precursors are partially unfolded or loosely folded polypeptide chains. Newly synthesized precursors are inhibited from spontaneously folding into their native conformation by the cytosolic chaperones, heat shock proteins 70 (Hsp70), and mitochondrial import stimulation factors (MSFs). Precursors bound to MSFs are guided to the TOM70-TOM37 receptors, while precursors bound to Hsp70  chaperones are targetted to TOM20-TOM22 receptor complexes.
Most of the mitochondrial precursors...
Translocation of Proteins into the Mitochondria01:19

Translocation of Proteins into the Mitochondria

Mitochondrial precursors are translocated to the internal subcompartments via independent mechanisms involving distinct protein machineries called translocases.
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...